Reaktion #519601

ord-2b5fdc26a1f24aa2a8a00ad881c1cbc3

Lösungsmittel

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    Sonstigethe solvent was evaporated
  2. 2
    Sonstigethe residue was purified by flash column chromatography

Vorschrift

trans-2-Phenyl-1-cyclopropanecarbonyl chloride (42 mg, 0.231 mmol) was added to a solution of 3-(4-amino-3-methoxyphenyl)-1-[1-(1-methylpiperidin-4-yl)-piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-4-amine (100 mg, 0.229 mmol) in pyridine (1.0 mL). After 5 hours, the solvent was evaporated and the residue was purified by flash column chromatography to give N1-{4-[4-amino-1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-2-methoxyphenyl}-trans-2-phenylcyclopropane-1-carboxamide (80 mg, 60%). 1H NMR (CDCl3) δ 1.42 (m, 1H), 1.77 (m, 2H), 1.85 (m, 2H), 2.06 (m, 3H), 2.36-2.45 (m, 8H), 2.62 (m, 1H), 3.00 (m, 2H), 3.10 (m, 2H), 3.96 (s, 3H), 4.75 (m, 1H), 5.54 (bs, 2H), 7.14-7.33 (m, 7H), 8.10 (s, 1H), 8.36 (s, 1H), 8.54 (d, J=8.50, 1H). LCMS (Finigan-Column: Pecosphere, C18, 3 um, 33×4.6 mm. Eluents: 0% B/A to 100% B/A in 4 min. (B: acetonitrile, A: 50 mM ammonia acetate buffer, pH 4.5), 3.0 mL/min.): MH+ =581.4, Rt=1.77 min.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US06660744B1uspto-grants-2003_12